Australia's most trusted
source of pharma news
Posted 4 March 2026 PM
Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences, and Arbutus Biopharma up to AU$3.21 billion (US$2.25 billion) to settle a long-running patent dispute over the technology that made its blockbuster Covid vaccine possible.
Under the settlement, Moderna will pay AU$1.35 billion (US$950 million) upfront in July 2026, resolving all US and international legal actions accusing Moderna of using lipid nanoparticle, or LNP, a ?delivery technology owned by Genevant and Arbutus, without permission in its Covid jab Spikevax and RSV jab mRESVIA.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.